MX2015005842A - Agente terapeutico para trastornos de queratoconjuntivitis. - Google Patents

Agente terapeutico para trastornos de queratoconjuntivitis.

Info

Publication number
MX2015005842A
MX2015005842A MX2015005842A MX2015005842A MX2015005842A MX 2015005842 A MX2015005842 A MX 2015005842A MX 2015005842 A MX2015005842 A MX 2015005842A MX 2015005842 A MX2015005842 A MX 2015005842A MX 2015005842 A MX2015005842 A MX 2015005842A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
corneal
disorders
keratoconjunctive
keratitis
Prior art date
Application number
MX2015005842A
Other languages
English (en)
Other versions
MX363111B (es
Inventor
Kazuhiro Kimura
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50684334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015005842(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of MX2015005842A publication Critical patent/MX2015005842A/es
Publication of MX363111B publication Critical patent/MX363111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)

Abstract

La invención actual aborda el problema de proporcionar un agente terapéutico novedoso para trastornos de queratoconjuntivitis. Como un medio para solucionar el problema, se proporciona un agente terapéutico para trastornos de queratoconjuntivitis que contiene un agonista RAR? como un ingrediente activo. El agente terapéutico exhibe un efecto de aminoración excelente en un modelo de trastorno de queratoconjuntivitis, y por lo tanto es útil como un agente terapéutico para trastornos de queratoconjuntivitis tales como úlcera de córnea, abrasión epitelial de córnea, queratitis, ojo seco, conjuntivitis, queratitis superficial crónica, erosión de córnea, trastornos persistentes de córnea, queratopatía punteada superficial, defectos epiteliales de la córnea, defectos epiteliales conjuntivales, queratoconjuntivitis seca, queratoconjuntivitis límbica superior, queratoconjuntivitis filamentosa, queratitis infecciosa, queratitis no infecciosa, conjuntivitis infecciosa y conjuntivitis no infecciosa. El agente terapéutico también es útil como un agente terapéutico para cicatrizado de córnea y cicatrizado conjuntival, ambos asociados con trastornos de queratoconjuntivitis.
MX2015005842A 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis. MX363111B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012246373 2012-11-08
PCT/JP2013/006563 WO2014073209A1 (ja) 2012-11-08 2013-11-07 角結膜障害の治療剤

Publications (2)

Publication Number Publication Date
MX2015005842A true MX2015005842A (es) 2016-01-20
MX363111B MX363111B (es) 2019-03-08

Family

ID=50684334

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005842A MX363111B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.
MX2019002526A MX2019002526A (es) 2012-11-08 2015-05-08 Agente terapeutico para trastornos de queratoconjuntivitis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019002526A MX2019002526A (es) 2012-11-08 2015-05-08 Agente terapeutico para trastornos de queratoconjuntivitis.

Country Status (17)

Country Link
US (6) US9492431B2 (es)
EP (1) EP2918290B1 (es)
JP (3) JP6254529B2 (es)
KR (1) KR102173932B1 (es)
CN (2) CN109589324B (es)
AU (2) AU2013342882B2 (es)
BR (1) BR112015010428B1 (es)
CA (1) CA2890424C (es)
CL (2) CL2015001225A1 (es)
ES (1) ES2834111T3 (es)
HK (1) HK1219224A1 (es)
MX (2) MX363111B (es)
NZ (1) NZ708756A (es)
RU (1) RU2659203C2 (es)
SG (2) SG10201704687YA (es)
WO (1) WO2014073209A1 (es)
ZA (1) ZA201504065B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
KR102303316B1 (ko) 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제
EA201892497A1 (ru) 2016-06-08 2019-05-31 Клементиа Фармасьютикалз Инк. Способы лечения гетеротопической оссификации
CN110381939B (zh) 2016-11-16 2022-12-02 同理制药公司 用于治疗多发性骨软骨瘤(mo)的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9306629A (es) 1993-01-11 1994-07-29 Ligand Pharm Inc Compuestos que tienen actividad selectiva para receptores retinoide x, medios para modulacion de procesos mediados pr receptores de retinoide x.
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
WO2001068135A2 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
JP4421293B2 (ja) 2001-09-18 2010-02-24 エフ．ホフマン−ラ ロシュ アーゲー アルキル尿素レチノイドアゴニストｉ
MXPA04002305A (es) 2001-09-18 2004-06-29 Hoffmann La Roche Agonistas ii de retinoides de urea sustituida.
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
EP1868576A2 (en) 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
WO2007113122A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CA2651487A1 (en) 2006-05-16 2007-11-29 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects
CN101687031B (zh) * 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
WO2008063842A2 (en) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) * 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
US20120121546A1 (en) 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
CN103702967A (zh) 2011-03-14 2014-04-02 貝丝以色列女执事医疗中心 用于治疗增殖性病症的方法和组合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
KR102303316B1 (ko) 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제

Also Published As

Publication number Publication date
CN105188753B (zh) 2018-12-18
RU2659203C2 (ru) 2018-06-28
EP2918290A4 (en) 2016-05-18
JP6254529B2 (ja) 2017-12-27
RU2015121628A (ru) 2016-12-27
JP6744389B2 (ja) 2020-08-19
AU2013342882A1 (en) 2015-06-11
EP2918290B1 (en) 2020-09-02
JPWO2014073209A1 (ja) 2016-09-08
MX363111B (es) 2019-03-08
CA2890424C (en) 2020-11-17
US10016395B2 (en) 2018-07-10
CN109589324B (zh) 2022-06-14
SG10201704687YA (en) 2017-07-28
CN105188753A (zh) 2015-12-23
US20230255937A1 (en) 2023-08-17
AU2013342882B2 (en) 2018-05-17
US10537556B2 (en) 2020-01-21
US9492431B2 (en) 2016-11-15
AU2018217197B2 (en) 2020-03-05
US20200345695A1 (en) 2020-11-05
US20190134002A1 (en) 2019-05-09
US20150290172A1 (en) 2015-10-15
KR20150082326A (ko) 2015-07-15
CL2015001225A1 (es) 2016-03-04
CN109589324A (zh) 2019-04-09
US11471440B2 (en) 2022-10-18
BR112015010428A2 (pt) 2017-07-11
WO2014073209A1 (ja) 2014-05-15
MX2019002526A (es) 2019-07-15
AU2018217197A1 (en) 2018-08-30
ZA201504065B (en) 2016-11-30
JP2019069992A (ja) 2019-05-09
US9750721B2 (en) 2017-09-05
EP2918290A1 (en) 2015-09-16
US20170065562A1 (en) 2017-03-09
HK1219224A1 (zh) 2017-03-31
BR112015010428B1 (pt) 2020-04-22
NZ708756A (en) 2019-07-26
CA2890424A1 (en) 2014-05-15
KR102173932B1 (ko) 2020-11-04
ES2834111T3 (es) 2021-06-16
CL2018001915A1 (es) 2018-08-31
US20180000782A1 (en) 2018-01-04
SG11201503612QA (en) 2015-06-29
JP2018030887A (ja) 2018-03-01
JP6462836B2 (ja) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2019002526A (es) Agente terapeutico para trastornos de queratoconjuntivitis.
MX2022004734A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
PH12016500791A1 (en) Novel amino pyrimidine derivatives
AU2016219611A1 (en) Compositions comprising mixtures of semifluorinated alkanes
MX2015009986A (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
MX2014004126A (es) Tratamiento de enfermedades malignas y no malignas con antagonistas de ras.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
MY166314A (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
RU2019104946A (ru) Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
PH12016500980A1 (en) Amide derivatives for gpr119 agonist
RU2012138767A (ru) Дисперсный композиционный материал
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
WO2011105902A3 (en) Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A3 (en) Antagonists of complement component 9 (c9) and uses thereof
RU2011145598A (ru) Цементная композиция для наливных полов с антистатическим эффектом